BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Giredestrant readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Giredestrant\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03332797-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Giredestrant: Phase 1 readout est. (NCT03332797)
DESCRIPTION:Giredestrant\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or 
 Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced o
 r Metastatic Estrogen Receptor-Positive Breast Cancer\nEstimated primary c
 ompletion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/giredestrant#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03332797
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Giredestrant: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Giredestrant\, phase 2.\nStudy: A Study Evaluating the Efficacy
  and Safety of Biomarker-Driven Therapies in Patients With Persistent or R
 ecurrent Rare Epithelial Ovarian Tumors\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/girede
 strant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04931342
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Giredestrant: Phase 3 readout est. (NCT06065748)
DESCRIPTION:Giredestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Evaluate Efficacy and Safety of Giredestrant Compared Wit
 h Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER-Positive
 \, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Th
 erapy (pionERA Breast Cancer)\nEstimated primary completion: 20 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06065748
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296798-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Giredestrant: Phase 3 readout est. (NCT05296798)
DESCRIPTION:Giredestrant\, phase 3.\nStudy: A Study to Evaluate the Efficac
 y and Safety of Giredestrant in Combination With Phesgo (Pertuzumab\, Tras
 tuzumab\, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Local
 ly Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)\nEstimate
 d primary completion: 15 June 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/giredestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05296798
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05708235-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Giredestrant: Phase 2 readout est. (NCT05708235)
DESCRIPTION:Giredestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using
  ctDNA in HR-positive/HER2-negative EBC Population\nEstimated primary comp
 letion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /giredestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05708235
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100106-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Giredestrant: Phase 1/2 readout est. (NCT07100106)
DESCRIPTION:Giredestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Evaluate the Effect of GDC-4198 Alone and in Combinatio
 n With Giredestrant Versus Abemaciclib and Giredestrant in Participants Wi
 th Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+)\, Human
  Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer\nEstimate
 d primary completion: 31 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/giredestrant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07100106
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827573-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Giredestrant: Phase 3 readout est. (NCT07827573)
DESCRIPTION:Giredestrant\, phase 3.\nStudy: A Study to Learn How Well Parti
 cipants With a Specific Type of Early Breast Cancer (ER-Positive\, HER2-Ne
 gative) Tolerate and Stay on Treatment With Giredestrant and How They Feel
  During Treatment\nEstimated primary completion: 30 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07827573
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Giredestrant: Phase 2 readout est. (NCT04557449)
DESCRIPTION:Giredestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study to Test the Safety and Tolerability of PF-07220060 in Particip
 ants With Advance Solid Tumors\nEstimated primary completion: 7 October 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04557449
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867262-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20300815
DTEND;VALUE=DATE:20300816
SUMMARY:Giredestrant: Phase 1 readout est. (NCT07867262)
DESCRIPTION:Giredestrant\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Evaluate the Effects of GDC-4198 in Combination With Letr
 ozole\, Fulvestrant\, or Giredestrant in Participants With Locally Advance
 d or Metastatic Hormone Receptor-Positive\, HER2-Negatve Breast Cancer\nEs
 timated primary completion: 15 August 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/giredestrant#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07867262
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Giredestrant: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Giredestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Patients With Metastatic or Locally Advanced Breast Cancer\
 nEstimated primary completion: 30 September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/giredestrant#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541079-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Giredestrant: Phase 3 readout est. (NCT07541079)
DESCRIPTION:Giredestrant\, phase 3.\nStudy: A Study Evaluating Adherence\, 
 Tolerability\, and Patient Reported Outcomes of Giredestrant in Participan
 ts With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aroma
 tase Inhibitor Therapy (novERA Breast Cancer)\nEstimated primary completio
 n: 30 June 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gire
 destrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07541079
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-9126@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Giredestrant: Phase 3 readout est. (NCT05862285)
DESCRIPTION:Giredestrant\, phase 3.\nStudy: A Rollover Study for Participan
 ts Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored
  Study\nEstimated primary completion: 1 March 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/giredestrant#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
